N‑2-Hydroxypropylmethacrylamide–Polycaprolactone Polymeric Micelles in Co-delivery of Proteasome Inhibitor and Polyphenol: Exploration of Synergism or Antagonism

• Published in: Molecular pharmaceutics 2023-01, Vol.20 (1), p.524-544
• Main Authors: Rani, Sarita, Sahoo, Rakesh K., Kumar, Vinay, Chaurasiya, Akash, Kulkarni, Onkar, Mahale, Ashutosh, Katke, Sumeet, Kuche, Kaushik, Yadav, Vivek, Jain, Sanyog, Nakhate, Kartik T., Ajazuddin, Gupta, Umesh
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - chemistry; Bortezomib - chemistry; Bortezomib - pharmacology; Cell Line, Tumor; Drug Therapy, Combination; Female; Leprostatic Agents - therapeutic use; Mice; Micelles; Polymers - chemistry; Proteasome Inhibitors - pharmacology; Proteasome Inhibitors - therapeutic use; Reactive Oxygen Species; Tissue Distribution
• ISSN: 1543-8384; 1543-8392
• DOI: 10.1021/acs.molpharmaceut.2c00752

Breast cancer leads to the highest mortality among women resulting in a major clinical burden. Multidrug therapy is more efficient in such patients compared to monodrug therapy. Simultaneous combinatorial or co-delivery garnered significant interest in the past years. Caffeic acid (CFA) (a natural polyphenol) has received growing attention because of its anticarcinogenic and antioxidant potential. Bortezomib (BTZ) is a proteasome inhibitor and may be explored for treating breast cancer. Despite its high anticancer activity, the low water solubility and chemical instability restrict its efficacy against solid tumors. In the present study, we designed and investigated a HP-PCL (N-2-hydroxypropylmethacrylamide–polycaprolactone) polymeric micellar (PMCs) system for the simultaneous delivery of BTZ and CFA in the treatment of breast cancer. The designed BTZ+CFA–HP-PCL PMCs were fabricated, optimized, and characterized for size, zeta potential, surface morphology, and in vitro drug release. Developed nanosized (174.6 ± 0.24 nm) PMCs showed enhanced cellular internalization and cell cytotoxicity in both MCF-7 and MDA-MB-231 cells. ROS (reactive oxygen species) levels were highest in BTZ–HP-PCL PMCs, while CFA–HP-PCL PMCs significantly (p < 0.001) scavenged the ROS generated in 2′,7′-dichlorofluorescein diacetate (DCFH-DA) assay. The mitochondrial membrane potential (MMP) assay revealed intense and significant green fluorescence in both types of cancer cells when treated with BTZ–HP-PCL PMCs (p < 0.001) indicating apoptosis or cell death. The pharmacokinetic studies revealed that BTZ–HP-PCL PMCs and BTZ+CFA–HP-PCL PMCs exhibited the highest bioavailability, enhanced plasma half-life, decreased volume of distribution, and lower clearance rate than the pure combination of drugs. In the organ biodistribution studies, the combination of BTZ+CFA showed higher distribution in the spleen and the heart. Overall findings of in vitro studies surprisingly resulted in better therapeutic efficiency of BTZ–HP-PCL PMCs than BTZ+CFA–HP-PCL PMCs. However, the in vivo tumor growth inhibition study performed in tumor-induced mice concluded that the tumor growth was inhibited by both BTZ–HP-PCL PMCs and BTZ+CFA–HP-PCL PMCs (p < 0.0001) more efficiently than pure BTZ and the combination (BTZ+CFA), which may be due to the conversion of boronate ester into boronic acid. Henceforth, the combination of BTZ and CFA provides further indications to be explored in the future to support the hy